Study with Diamyd Medical’s diabetes vaccine awarded

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 27, 2014 at 2:45 AM

Study with Diamyd Medical’s diabetes vaccine awarded EU-funding

Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) informs that the ongoing combination study DIABGAD has been awarded EUR 120 000, corresponding to about SEK 1.1 million, in EU-funding. The grant comes from an FP7 project where Linköping University and Diamyd Medical are included. The DIABGAD study aims to evaluate whether vitamin D and ibuprofen act synergistically with the diabetes vaccine Diamyd® in order to preserve the insulin producing capacity in children newly diagnosed with type 1 diabetes. The first results from the study are expected to be presented in the beginning of 2015. “It is truly encouraging that the EU chooses to support DIABGAD,” says Professor Johnny Ludvigsson at Linköping University, who is the lead investigator and sponsor of the study. “This funding helps and strengthens us in our efforts to reach a new combination therapy for type 1 diabetes.” “The combination program for the diabetes vaccine Diamyd® is of interest to both researchers and industry,” says Anders Essen-Möller, Chairman of Diamyd Medical. “The funding from the EU reflects this and the concept will be discussed further with Diamyd Medical's Scientific Advisory Board on September 16 in conjunction with a European diabetes conference in Vienna.” Type 1 diabetes is an autoimmune disease where the immune system attacks the patients’ own insulin producing beta cells. For these patients, daily treatment with insulin is mandatory to sustain life. The importance of finding a cure is high for the world’s health care systems and the wellbeing of patients. The annual market for an easy to use, successful therapeutic is estimated to several billion dollars. About Diamyd® Diamyd® is a therapeutic under development for the treatment and prevention of autoimmune diabetes. Diamyd® has been used in trials totaling more than one thousand patients with an excellent safety profile. Diamyd has shown an overall 16% efficacy (p=0.1) versus placebo regarding preservation of the patients’ endogenous insulin secretion in a European Phase III trial and is currently being further developed in combination regimens with other therapeutic compounds. Diamyd® is easy to administer in any clinical setting. For further information, please contact: Anders Essen-Möller, Chairman Diamyd Medical AB Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com About Diamyd Medical Diamyd Medical is dedicated to fight type 1 diabetes and to work towards a cure for the disease. Diamyd Medical’s current projects include development of combination regimens for arresting the successive destruction of insulin producing beta cells using the Company’s GAD65-based diabetes vaccine, such as for example Diamyd®+ Vitamin D with or without an anti-inflammatory compound; and Diamyd®+ GABA, for which Diamyd Medical licenses exclusive intellectual rights from the University of California in Los Angeles (UCLA). Diamyd Medical has further acquired 46% of the stem cell company Cellaviva AB that is establishing a Swedish commercial bank for private family saving of umbilical cord blood and other sources of stem cells. Stem cells are required for Personalized Regenerative Medicine (PRM), for example to restore beta cell mass in diabetes patients where autoimmunity has been arrested. Remium Nordic AB is the Company’s Certified Adviser. Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pete Crow-Armstrong Unveils Signature Baseball Gloves

The Windy City Meets the Diamond Alright, bear with me here. Monday morning vibes, right? But here's something that'll turn your breakfast around if you're into baseball—or just the latest scoop on players making waves in gear. Pete Crow-Armstrong, the Chicago Cubs center fielder who's been lighting up the field, has his name on some fresh gear. We're talking signature...

Pet Care Spending Defies Economic Pressures, Survey Shows

Consumer Loyalty to Pet Health Spending Stands Tall When it rains, it pours, but try telling that to pet owners. According to Elanco Animal Health's latest data dump, 93% of surveyed pet owners in the U.S. are guarding their pet health spending like a hawk. Yep, they either maintained or upped their spending in the past three months—and they ain't planning to back down...

F&G Boosts Dividend for Investors in Strong Signal

Ring the Bell: Dividend Hike from F&G F&G Annuities & Life (NYSE: FG) just raised its dividend, and every investor worth their salt knows that means something. A 4% bump up to $0.26 per common share might not sound like a fanfare, but in the land of finance, it's an indication that this company thinks it's riding a positive wave. It’s like getting a little bonus in your...

Tenax Therapeutics Faces Securities Fraud Class Action

Where Did It All Go Wrong for Tenax? They say the stock market is a rollercoaster, but Tenax Therapeutics, Inc. (NASDAQ: TENX) seems to have taken that expression way too literally. Imagine watching your investments tumble by nearly 90% in a single day. On August 10, 2026, that was the grim reality for Tenax's stockholders when the company's shares plummeted from over $13...

Window-Cleaning Robots: Revolution or Gimmick?

The Rise of Robotic Window Cleaners Innovation is a funny thing. Just when you think life couldn't get any easier, here come robots to wipe your windows cleaner than any elbow grease ever has. Now, I'd never have pegged window-cleaning as a battleground for household tech, but look at how the market's shifting in China. From 480 million yuan in 2020 to a whopping 1.7...

CorelDRAW's Flexibility: A Designer's One-Time Buy?

CorelDRAW: A Design Powerhouse Without Recurring Bills? Every so often, a software option comes along that piques my interest, and right now, it's CorelDRAW Graphics Suite. Consumer365 has shone a light on this nifty tool for its one-time purchase model—a breath of fresh air in the age of endless subscriptions that seem to drain more than enthusiasm as the months roll...

Education Cannot Wait Nears US$600M Goal in Geneva

Global Support Bolsters Education Cannot Wait Just when you think the world’s going sideways, some stories give you a dash of hope. The recent pledges at the Geneva conference have pumped Education Cannot Wait (ECW) up to 90% of the US$600 million goal. That’s some progress in tight times. With US$405.8 million freshly announced, they’ve got US$541.6 million in the...

Tripadvisor Faces Investigation Over Securities Violations

Tripadvisor's Stock Dive: Investor Panic or Opportunity? Woah, if you had a stake in Tripadvisor (NASDAQ: TRIP) recently, you know it hasn't been a walk in the park. Shares took a nosedive of over 20% on November 5, 2026, after they unveiled a frightening $313.1 million net loss for the third quarter. What stirred the pot, you ask? Well, toss in a goodwill impairment...

Curis Prepares for Q3 2026 Results Amid Tough Sector Trends

All Eyes on Curis as Q3 Financials Loom Just when you think you’ve seen it all in this wild biotech ride, Curis, Inc. (NASDAQ: CRIS) is prepping to roll out their third quarter financial and operating results. Circle your calendars for November 12, 2026, because the clock’s ticking down to their 4:00 p.m. ET announcement, swiftly followed by a conference call at 4:30...

XCMG Spurs 'AI + Construction' Innovation at Event

XCMG's Big Push for Smarter Machinery China's construction machinery titan XCMG just wrapped up a fireworks show of innovation in Xuzhou, highlighting some sharp AI-driven machinery projects. Their recent 'AI + Construction Machinery' competition pulled in minds from over 20 countries, all aiming to rethink how these hulking machines operate. AI and Machinery: A Match...